Concepedia

Jane Healy

JH

12

Publications

1.8K

Citations

11

H-Index

2007

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

The University of Texas MD Anderson Cancer Center

Duke University

Duke Medical Center

Howard Hughes Medical Institute

Jane Healy is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, immunology, and physiology.

Top concepts

Publications per year

2007–2024

12

Publications

12

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma

Anupama Reddy, Jenny Zhang, Nicholas S. Davis et al. · Cell · 2017 · 1.1K citations · Full text

, , +9

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆

Jiaxin Niu, Corinne Maurice‐Dror, D.H. Lee et al. · Annals of Oncology · 2021 · 273 citations · Full text

Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2

Andrea B. Moffitt, Sarah L. Ondrejka, Matthew McKinney et al. · The Journal of Experimental Medicine · 2017 · 170 citations · Full text

GNA13 loss in germinal center B cells leads to impaired apoptosis and promotes lymphoma in vivo

Jane Healy, Adrienne Nugent, Rachel E. Rempel et al. · Blood · 2016 · 63 citations · Full text

A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.

Elena Garralda, Ammar Sukari, Nehal J. Lakhani et al. · Journal of Clinical Oncology · 2021 · 46 citations

, , +20

Rows per page

1–5 of 12